The global nitric oxide asthma testing market was anticipated to reach a valuation of US$ 2.4 Billion in the year 2022. With a steady CAGR of 4.7% from 2023 to 2033, this market is expected to reach US$ 2.51 Billion by 2023 and US$ 3.98 Billion by 2033.
The FeNO test is another name given to the nitric oxide asthma test. FeNO, which stands for fractional exhaled nitric oxide, is a test that gauges a person's nitric oxide levels while they are breathing. Nitric oxide levels that are high in exhaled air may indicate irritated airways. In patients with allergic or eosinophilic asthma, a Feno Test, also known as an exhaled nitric oxide test, can be used to assess how much pulmonary inflammation is prevalent as well as whether inhaled steroids are controlling this inflammation.
Bronchospasm, breathlessness, and reversible airflow blockage are frequent symptoms of asthma, a chronic disorder that stretches and then narrows the lungs' airways. Increasing cigarette use is a factor in asthma attacks. Also, as industrialization has advanced, more occurrences of asthma and COPD have been reported, which may raise the need for nitric oxide asthma testing in the coming years.
According to a 2021 article in the journal JGH, 300 to 400 million individuals worldwide are thought to have asthma. Due to rising smoking rates, household and surrounding air pollution, and other exposures, as well as large and expanding populations, the growing burden of asthma particularly worries low- and middle-income countries (LMICs). Hence, it is anticipated that the expansion of this market would be fueled by the rising incidence of asthma patients and the high reliance of the general public on nitric oxide to treat the symptoms.
Due to the large population of asthma patients, the nitric oxide asthma testing market in North America is anticipated to have a significant revenue share in the worldwide nitric oxide asthma testing market. The proliferation of the target market is anticipated to be impacted by the huge range of companies operating in the nation and the accessibility of cutting-edge infrastructure for the acceptance of cutting-edge technologies. In addition, the market for nitric oxide asthma testing is anticipated to develop as leading competitors strengthen their company acquisition efforts to boost revenue share and enhance product offerings.
Nitric oxide asthma testing market growth is being favorably impacted by leading players' strategic business expansion efforts to gain revenue share and boost product portfolio through innovative product launches. Manufacturer of medical equipment Caire Inc. purchased Spirosure Inc. in 2020. The goal of the purchase is to apply Spirosure's technology to the company's portfolio of market-leading oxygen solutions. The corporation anticipates that this purchase will improve operations and boost revenue.
Increased research and development in this domain are also expected to fuel the market growth from 2023 to 2033. In addition, Zylo Therapeutics Inc. received a two-year, USD 600,000 Small Business Innovation Research (SBIR) grant in August 2022 for developing the company's final formulation of a novel topical medication for the treatment of onychomycosis that releases nitric oxide. The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, is funding the award. To further its nitric oxide-based medicines pipeline, SaNOtize Research & Development Inc. obtained an oversubscribed USD 24 million Series B fundraising in August 2022. The company's nitric oxide nasal spray (NONS), which has already been demonstrated in clinical tests to cure and avoid COVID-19 infection, is the principal therapeutic under development. Such innovations are sure to bring forth new opportunities during the forecast period.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 2.51 Billion |
| Expected Market value in 2033 | US$ 3.98 Billion |
| Growth Rate (2023 to 2033) | 4.7% |
Nitric oxide asthma testing is used for the diagnosis and treatment of asthma. Nitric oxide is a gaseous molecule produced as an inflammatory response by various types of cells. The concentration of exhaled nitric oxide in breathe acts as a biomarker for diagnosis, treatment and management of asthma by determining the airway inflammation. A higher amount of nitric oxide is exhaled during the inflammation in asthma patients.
The global nitric oxide asthma testing market is expected to grow during the forecast period with the increasing number of asthma patients. The outbreak of novel coronavirus has caused a disturbance in almost all the industries. The novel coronavirus has also affected the nitric oxide asthma testing market. It has been observed that people with asthma are more vulnerable to coronavirus disease.
Since a huge number of population is suffering from asthma across the globe, it has led to an increase in the demand to manage asthma which in turn is driving the growth of the nitric oxide asthma testing market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising prevalence of asthma is fueling the growth of the nitric oxide asthma testing market. There has been a significant growth in the use of several types of equipments and diagnostic devices in hospitals and clinics which is driving the growth of the nitric oxide asthma testing market.
The demand for quick and easy diagnosis of asthma is also driving the nitric oxide asthma testing market. Furthermore, the availability of affordable products and services for the diagnosis of asthma is likely to influence the growth of the nitric oxide asthma testing market. The lack of knowledge about nitric oxide asthma testing in developing nations across the globe restrains the growth of the nitric oxide asthma testing market.
Based on the product type, nitric oxide testing handheld monitor is expected to be the most preferred product in the nitric oxide asthma testing market. Based on the end-user, global nitric oxide asthma testing is widely used in the hospitals and the clinics due to the higher number of patients flow.
The nitric oxide asthma testing is evolving to provide a complementary role alongside existing pulmonary function tests. Nitric oxide asthma testing is widely used in the market to determine what kind of asthma you have, whether the patient is taking medicines correctly, the dosage of medicines should be increased or reduced.
It also helps to track the airway inflammation over time. Role of exhaled nitric oxide in determining optimum steroid requirement in chronic asthma is the important area for future research in the nitric oxide asthma testing market.
Principal Consultant
North America and Europe are expected to dominate the global nitric oxide testing market, due to the increasing demand for asthma diagnostic services and rising demand for medical devices and instruments in healthcare institutes and diagnostic laboratories.
Also, high prevalence rates of asthma and allergic diseases are expected to increase the growth of the nitric oxide asthma testing market in these regions. Increase in healthcare expenditure in the developing region like Asia-Pacific is expected to push the global nitric oxide asthma testing market growth over the forecast period.
Some of the market key players operating in the global nitric oxide asthma testing market identified across the value chain include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Healthcare
January 2023
REP-GB-16488
296 pages
Explore Healthcare Insights
View Reports
Nitric Oxide Asthma Testing Market
